Navigation Links
Caris Life Sciences nimmt Next-Generation Sequencing zur Verbesserung des evidenzbasierten Tumorprofilierungsservices für Krebspatienten auf
Date:1/28/2013

ebnisse bei einem kleineren Prozentsatz von Krebspatienten bieten, aber der behandelnde Arzt sieht nur einen Teil des gesamten molekularen Bildes. Im Gegensatz dazu bietet Caris eine aussagekräftigere Biomarkeranalyse und stellt erheblich bessere Ergebnisse durch eine gründliche Untersuchung wichtiger Biomarker in der Krebsbahn bereit. Des Weiteren erlaubt der Ansatz von Caris die Einhaltung der FDA-Kennzeichnung bei genehmigten begleitdiagnostischen Verfahren."

Mit bis heute über 45,000 profilierten Patienten besitzt Caris Life Sciences die umfassendste Sammlung von Biomarkerprofilen der gesamten Branche. Weit über die ganz offensichtlichen Auswirkungen auf die Forschung hinausgehend, bietet diese umfassende Datenbank Klinikern wichtige Informationen über das Vorkommen von Biomarkern in unerwarteten Krankheitsstadien und erlaubt es ihnen, personalisierte, maßgeschneiderte Therapien für ihre Patienten auszuwählen.

Über Caris Life Sciences
Caris Life Sciences ist ein führendes biowissenschaftliches Unternehmen, das sich auf die Einführung von personalisierter Medizin konzentriert. Der Molecular Intelligence™ Service (MI Profile™) von Caris vergleicht molekulare Daten, die vom Tumor eines Patienten erzeugt werden, mit den Biomarkern/Arzneimittelassoziationen der führenden klinischen Krebsliteratur der Welt. Der Service verwendet dabei die fortschrittlichsten und klinisch relevantesten Technologien, um Ärzte mit Informationen zu versorgen, die sie bei der Auswahl jener personalisierten Krebstherapien unterstützen, die wahrscheinlich bei den Patienten erfolgreich sein werden. Caris entwickelt ebenfalls eine Reihe von Bluttests, die auf der Carisome® Plattform aufbauen - eine blutbasierte Prüftechnik für die Diagnose, Prognose und Theranose von Krebs und anderen komplexen Erkran
'/>"/>

SOURCE Caris Life Sciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
2. Caris Sponsors CancerCare Connect Education Workshop on Molecular Profiling in the Treatment of Breast Cancer
3. Caris Life Sciences mejora la evaluación por perfil molecular con los biomarcadores ROS1 y MGMT-metilación
4. Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
5. Multi-Axes Cartesian Robotic Platform for Life Sciences Automation
6. Indiana’s Life Sciences Industry Economic Impact Tops $50 billion
7. GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
8. Atharva Lifesciences Consulting Releases the Biggest Ever Compilation of Science Funding Sources for India
9. SeraCare Life Sciences Divests Biorepository Business
10. SeraCare Life Sciences Sharpens Focus on Diagnostics Industry
11. Breakthrough Book From GLS Sciences Ends Blood Sugar Abuse in Time For The Holidays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 GlassesOff ... image processing functions in the human vision system, announced today ... point guard Chris Paul to develop a ... who want to improve their real-life on-court performance. ... court, whether it is shooting a ball or blocking a ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... customers’ weighing needs and expertly narrows down the product choices to a manageable ... criteria pares down the list to models that fit best with the customer’s ...
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... April 23 Government and private insurers are placing ... for the products they develop, according to The 2009 ... governments and individuals are likely to increase demands to ... mounting healthcare costs, a shrinking tax base, aging populations, ...
... /PRNewswire-Asia-FirstCall/ --, - Fourth Quarter 2008 Revenue Increased 28.6% to ... and Diluted EPS of $.03, - 2008 Revenues Increased 23.5% ... Improved 340 Basis Points to 20.1%, - 2008 Net Income ... $0.13, - 2008 Cash Flow from Operations was $5.9 ...
... 2009 came to a close were forced to announce layoffs, and the U.S. ... rest of the country as job creation for March contracted by 50 percent. ... ... came to a close in March, several companies announced layoffs, and while many ...
Cached Biology Technology:Failing to Demonstrate Value of Innovation is Top Risk Facing Life Sciences Sector, According to Ernst & Young 2Failing to Demonstrate Value of Innovation is Top Risk Facing Life Sciences Sector, According to Ernst & Young 3Failing to Demonstrate Value of Innovation is Top Risk Facing Life Sciences Sector, According to Ernst & Young 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 2China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 5China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 6China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 7China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 8China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 9China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 10China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 11The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 3The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 4
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... the Appalachian Mountains is a tiger swallowtail butterfly that ... ago. It,s a rarity in the animal world, ... tiger swallowtail, Papilio appalachiensis, evolved from mixing between the ... and the Canadian tiger swallowtail, P. canadensis . ...
... HOUSTON -- Gene therapy delivered directly to a particularly ... to self-destruct, lowers chance of recurrence and helps increase ... The University of Texas MD Anderson Cancer Center reported ... . In cellular and mouse studies, scientists found ...
... 12, 2011A study presented today by Universit Laval researchers at ... Quebec City revealed that the risk of insomnia is 67% ... member is an insomniac. The research team, directed ... Psychology, came to these conclusions following a study involving 3,485 ...
Cached Biology News:A tale of (more than) 2 butterflies 2A tale of (more than) 2 butterflies 3Gene therapy kills breast cancer stem cells, boosts chemotherapy 2Gene therapy kills breast cancer stem cells, boosts chemotherapy 3
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Profilin-1/2 (FL-140)...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: